

CORRECTION

Open Access



Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Daniel H. Johnson¹, Chrystia M. Zobniw², Van A. Trinh², Junsheng Ma³, Roland L. Bassett Jr³, Noha Abdel-Wahab^{4,5}, Jaime Anderson², Jennifer E. Davis⁶, Jocelyn Joseph², Marc Uemura¹, Ali Noman⁷, Hamzah Abu-Sbeih⁷, Cassian Yee¹, Rodabe Amaria¹, Sapna Patel¹, Hussein Tawbi¹, Isabella C. Glitza¹, Michael A. Davies¹, Michael K. Wong¹, Scott Woodman¹, Wen-Jen Hwu¹, Patrick Hwu¹, Yinghong Wang^{7†} and Adi Diab^{1*†}

Correction to: J Immunother Cancer

<https://doi.org/10.1186/s40425-018-0412-0>

Following publication of the original article [1], the authors reported an error in their listed affiliations. This error was introduced during typesetting and the publisher apologizes to readers and the authors for the inconvenience.

In this Correction the authors are listed with their correct affiliations below.

Daniel H Johnson¹, Chrystia M Zobniw², Van A Trinh², Junsheng Ma³, Roland L Bassett Jr³, Noha Abdel-Wahab^{4,5}, Jaime Anderson², Jennifer E Davis⁶, Jocelyn Joseph², Marc Uemura¹, Ali Noman⁷, Hamzah Abu-Sbeih⁷, Cassian Yee¹, Rodabe Amaria¹, Sapna Patel¹, Hussein Tawbi¹, Isabella C Glitza¹, Michael A Davies¹, Michael K Wong¹, Scott Woodman¹, Wen-Jen Hwu¹, Patrick Hwu¹, Yinghong Wang⁷ and Adi Diab¹

¹Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

²Division of Pharmacy, Clinical Section, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

³Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁴Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁵Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt

⁶Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁷Department of Gastroenterology, Hepatology, and Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Author details

¹Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ²Division of Pharmacy, Clinical Section, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ³Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁴Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁵Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt. ⁶Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁷Department of Gastroenterology, Hepatology, and Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Received: 27 November 2018 Accepted: 29 November 2018

Published online: 17 April 2019

Reference

1. Johnson DH, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. *J Immunother Cancer*. 2018;6:103 <https://doi.org/10.1186/s40425-018-0412-0>.

* Correspondence: adiab@mdanderson.org

[†]Yinghong Wang and Adi Diab contributed equally to this work.

¹Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Full list of author information is available at the end of the article

